Posted by Michael Wonder on 27 Feb 2026
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria
27 February 2026 - Novartis announced today that the CHMP of the EMA has adopted a positive opinion recommending marketing authorisation for remibrutinib.
The opinion supports its use as an oral treatment for chronic spontaneous urticaria in adult patients with inadequate response to H1‑antihistamine treatment.
